Crisis in CRISPR world, RFK Jr.’s promises, and a novel non-opioid pain drug

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he’s confirmed to lead the Department of Health and Human Services? And how do you pronounce Journavx?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We bring on our colleague Jason Mast to discuss the dramatic downturn in the once-swaggering field of CRISPR gene editing.

We also talk about the advancement of RFK Jr.’s nomination to be HHS secretary, the latest pharma earnings, and the approval of a non-opioid pain drug from Vertex Pharmaceuticals.

For more on the challenges in the CRISPR field, go here; to read more about RFK Jr.’s goals and challenges ahead, go here; and to learn more on Vertex’s approval, go here.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, TuneIn, or wherever you get your podcasts.

Canadian Wildfire Smoke Increased Asthma-Related ED Visits in the U.S.

Exposure to smoke originating from the Canadian wildfires led to a rise in asthma-associated emergency department (ED) visits in the U.S., with a large spike

August 26, 2023

Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance – Biotech Investments

Evolva Holding SA / Key word(s): Strategic Company Decision 14-Jun-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The

June 15, 2023

MemorialCare Deploys Abridge’s GenAI Clinical Documentation Across Enterprise

What You Should Know: – MemorialCare, a healthcare system in Southern California, announced today a partnership with Abridge, a company pioneering the use of generative

April 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.